Press "Enter" to skip to content

Fate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy – GlobeNewswire

admin 0

Fate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy  GlobeNewswire

FT596 Product Candidate Derived from Clonal Master iPSC Line Engineered with Three Anti-Tumor Functional Components. Designed to Overcome CD19 …

“lymphoma cancer” – Google News

(Visited 5 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *